On June 28, the Substance Abuse and Mental Health Services Administration (SAMHSA) announced that Opioid Treatment Programs (OTPs) can continue virtual buprenorphine prescribing for both new and existing patients even after the federal COVID-19 public health emergency (PHE) ends. This means OTPs can maintain telemedicine services without requiring an initial in-person medical evaluation for up to one year post-PHE. This decision marks a significant step in transforming opioid use disorder (OUD) treatment and reflects growing confidence in the safety and effectiveness of virtual buprenorphine prescribing.
While this extension excludes methadone—which still requires an in-person medical evaluation—the flexibility granted to buprenorphine prescribing is a sign of how telehealth is reshaping addiction care and improving access for many patients who previously faced barriers to treatment.
How Virtual Buprenorphine Prescribing Revolutionized Access to Care During the Pandemic
The COVID-19 pandemic disrupted healthcare delivery in unprecedented ways, forcing providers and regulators to rethink traditional models of care. In April 2020, SAMHSA issued an exemption allowing OTPs to prescribe buprenorphine virtually without an in-person visit, provided telehealth could adequately supervise patients. This exemption was critical during the public health emergency, ensuring that patients with opioid use disorder could continue treatment despite lockdowns and social distancing.
The rise of virtual buprenorphine prescribing during this period has had profound effects. Patients who may have been reluctant or unable to visit clinics in person suddenly had access to lifesaving medications via telemedicine. Providers reported fewer missed appointments and improved patient engagement. The flexibility of virtual care allowed people living in rural areas or those facing transportation challenges to maintain consistent treatment.
As a result, virtual buprenorphine prescribing became a cornerstone of medication-assisted treatment (MAT) during the pandemic, creating a new pathway that many expect to continue long-term.
Why Virtual Buprenorphine Prescribing Does Not Extend to Methadone
Despite the progress with buprenorphine, methadone remains subject to stricter federal regulations. According to SAMHSA’s June announcement, the in-person medical evaluation requirement for methadone persists. Methadone is dispensed exclusively through federally certified OTPs and has historically been more tightly controlled due to concerns about safety and diversion.
This continued in-person requirement for methadone has raised questions and debates among treatment advocates, clinicians, and patients. Many argue that expanding virtual buprenorphine prescribing to include methadone would further reduce barriers and save lives. However, regulators remain cautious, balancing the benefits of telehealth with patient safety concerns.
The differentiation between these medications highlights ongoing regulatory challenges in modernizing addiction treatment while ensuring oversight.
The Positive Impact of Virtual Buprenorphine Prescribing on Patients and Providers
Since the initial exemption in 2020, states, OTPs, clinicians, and patients have overwhelmingly reported positive outcomes from virtual buprenorphine prescribing. According to SAMHSA, this flexibility has led to improved patient satisfaction and higher engagement rates.
Virtual buprenorphine prescribing removes many traditional obstacles such as transportation difficulties, work or childcare conflicts, and stigma associated with visiting addiction clinics. Patients can now access care discreetly and conveniently from their homes, increasing treatment retention and adherence.
Providers also benefit from the ability to reach a broader patient population, especially in underserved areas. Virtual prescribing allows for more efficient scheduling and follow-ups, enabling clinicians to better manage caseloads and focus on patient outcomes.
The success stories and positive feedback surrounding virtual buprenorphine prescribing have been a driving force behind SAMHSA’s decision to extend the policy beyond the PHE.
The Role of Virtual Buprenorphine Prescribing in Expanding Telehealth for Behavioral Health
The extension of buprenorphine prescribing aligns with broader trends in behavioral health, where telehealth utilization has seen unprecedented growth. Addiction treatment was one of the fastest-growing sectors for telemedicine during the pandemic, and many stakeholders now view virtual care as essential to meeting ongoing demand.
Virtual buprenorphine prescribing has empowered both traditional facility-based providers and innovative digital health startups. Companies like Boulder Care and Bicycle Health have built scalable virtual MAT programs that integrate medication management with counseling and peer support—all delivered remotely.
This growing ecosystem demonstrates that virtual buprenorphine prescribing not only improves access but also supports integrated care models that address the complexities of opioid use disorder in a holistic way.
What This Extension Means for the Future of Addiction Treatment
SAMHSA’s announcement granting up to one year of continued virtual buprenorphine prescribing post-PHE is more than a temporary fix—it signals a potential paradigm shift. Policymakers and regulators now have the opportunity to evaluate long-term data on safety, efficacy, and patient outcomes from virtual care.
Many experts expect that, if these positive trends continue, buprenorphine prescribing will become a permanent feature of the addiction treatment landscape. Such a move would ensure sustained access to medication-assisted treatment for millions of Americans.
However, challenges remain, including addressing equity in telehealth access, ensuring quality of care, and reconsidering methadone regulations. Continued advocacy and research will be vital to guide balanced policy decisions.
Why Virtual Buprenorphine Prescribing Matters in Combating the Opioid Epidemic
The opioid epidemic remains a devastating public health crisis, with overdose deaths reaching record levels, fueled by synthetic opioids like fentanyl. Timely access to treatment can mean the difference between life and death.
Virtual buprenorphine prescribing reduces barriers that prevent many people from seeking help. By allowing patients to initiate and continue MAT remotely, this approach increases the likelihood that individuals will engage in care before reaching a crisis point.
Moreover, virtual prescribing respects patient privacy and autonomy, reducing stigma and empowering individuals to take control of their recovery journey. It has become a crucial tool in the effort to reduce opioid-related harm nationwide.
Conclusion: Virtual Buprenorphine Prescribing Is Here to Stay
SAMHSA’s extension of buprenorphine prescribing after the public health emergency is a landmark development. It reflects a growing understanding that addiction treatment must evolve to meet patients’ needs in a modern, digital world.
By continuing to allow OTPs to prescribe buprenorphine virtually, the federal government acknowledges the power of telehealth to increase access, improve outcomes, and save lives. While questions remain around methadone and permanent regulations, the future of buprenorphine prescribing looks promising.
For patients, providers, and the broader addiction treatment community, this extension offers hope for a more accessible and compassionate system of care—one where evidence-based treatment is never out of reach.
 during the pandemic, creating...){kind=link}